Pulmatrix Secures $14,000,000 Series B Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    99 Hayden Avenue Lexington, MA 02421
  • Company Description
    Pulmatrix Inc. is a pharmaceutical company developing inhalable aerosols and enabling technologies that help control respiratory infectious disease and human-source airborne contamination.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will enable Pulmatrix to accelerate its lead iCALM drug candidate, PUR118, through Phase 2A efficacy studies in two diseases, chronic obstructed pulmonary disease (COPD) and cystic fibrosis (CF).
  • M&A Terms
  • Venture Investor
    Polaris Venture Partners
  • Venture Investor
    5AM Ventures
  • Venture Investor
    ARCH Venture Partners
  • Venture Investor
    Novartis BioVenture Fund

Trending on Xconomy